MDCO : Summary for The Medicines Company - Yahoo Finance

U.S. Markets closed

The Medicines Company (MDCO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
34.85+2.03 (+6.19%)
At close: 4:00 PM EST
People also watch:
NBIXUTHRNKTRALKSLGND
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close32.82
Open34.58
Bid30.85 x 200
Ask35.80 x 500
Day's Range34.35 - 35.88
52 Week Range27.50 - 41.79
Volume1,304,574
Avg. Volume1,341,192
Market Cap2.42B
Beta0.18
PE Ratio (TTM)-11.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Lexmark International Inc (LXK) A Good Stock To Buy Right Now?
    Insider Monkey5 days ago

    Is Lexmark International Inc (LXK) A Good Stock To Buy Right Now?

    Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]

  • Hedge Funds Are Betting On The Medicines Company (MDCO)
    Insider Monkey8 days ago

    Hedge Funds Are Betting On The Medicines Company (MDCO)

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC
    Investor's Business Daily8 days ago

    Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC

    Biotech stocks will likely close 2016 down by double digits, but 2017 is filled with catalysts, RBC analyst Adnan Butt says.